Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Building on this discovery, researchers have designed a new treatment that showed promise in a study of mice.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
Could new cancer drugs restore immune responses against HIV?
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.
Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
A genomic sequencing program revealed a genetic mutation that was able to be successfully treated with a checkpoint inhibitor.
An early study conducted among those with indolent lymphoma showed promising results.
Study finds that having more diverse gut bacteria was associated with better response to immunotherapy.
The discovery may help explain immunotherapy resistance and hints at new therapies.
Two types of immunotherapy plus chemotherapy shrank tumors in most patients in an early study.
In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.